Nonpeptide somatostatin type 5 receptor agonists and uses thereof

Inventors

Zhao, Jian • ZHU, Yunfei • Wang, Shimiao • Chen, Mi • Pontillo, Joseph

Assignees

Crinetics Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12600709-B2

Patent

Publication Date

2026-04-14

Expiration Date


Abstract

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Core Innovation

The independent claim covers a method of treating hyperinsulinism in a mammal in need thereof by administering 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof. Dependent claims identify congenital hyperinsulinism and drug-induced hyperinsulinism as specific forms addressed by the method. The background problem intended to be solved is not explicitly described in the patent.

The disclosed subject matter concerns nonpeptide somatostatin receptor modulators, particularly compounds that selectively activate SSTR5, presented for oral pharmaceutical formulations, administration routes, and treatment of somatostatin-responsive conditions. The text associates SSTR5 activity with inhibition of insulin and growth-hormone secretion. Disclosed examples describe amino-methylpyrrolidine pyridine-carboxamide compounds, including compound 1-192, with reported SST5 potency below 10 nM and SST5-over-SST2 selectivity of 10–99-fold.

Claims Coverage

The supplied claims identify one independent claim directed to a method of treating hyperinsulinism in a mammal. One inventive feature is identified.

Treatment of hyperinsulinism with the specified pyridine-3-carboxamide compound

A method of treating hyperinsulinism in a mammal in need thereof by administering 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof. Dependent claims specify congenital hyperinsulinism or drug-induced hyperinsulinism.

The claim coverage centers on administering the specified pyridine-3-carboxamide compound or its pharmaceutically acceptable salt to treat hyperinsulinism in a mammal, specifically addressing congenital or drug-induced hyperinsulinism.

Stated Advantages

Potential advantages over peptide analogs include avoiding costly depot injections, visits associated with those injections, and injection-site reactions.

Documented Applications

Treatment of hyperinsulinism in a mammal, including congenital hyperinsulinism and drug-induced hyperinsulinism.

Treatment of somatostatin-responsive conditions benefiting from somatostatin modulation, expressly including hyperinsulinemic hypoglycemia.

Proposed testing of SST5 agonists in SUR1−/− hyperinsulinism models, with no in vivo efficacy results reported in the partial content.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.